Most SIBO testing focuses on detecting the overgrowth itself through breath tests that measure hydrogen, methane, and hydrogen sulfide gases. The ibs-smart test takes a different approach. Instead of asking whether bacteria are currently overgrown in the small intestine, it asks why the overgrowth is happening in the first place. By measuring antibodies linked to post-infectious autoimmune damage, ibs-smart identifies the motility defect that allows bacteria to accumulate. For patients caught in a cycle of SIBO treatment and relapse, this distinction can change the entire treatment strategy.
What does the ibs-smart test measure?
The ibs-smart test is a simple blood draw that measures two antibodies using enzyme-linked immunosorbent assay (ELISA) technology. The first is anti-CdtB (anti-cytolethal distending toxin B), which indicates that the patient was exposed to a food poisoning bacterium that produces CdtB toxin, such as Campylobacter jejuni, Shigella, Salmonella, or certain E. coli strains. The second is anti-vinculin, which indicates that the molecular mimicry process has been activated and the immune system is producing antibodies that cross-react with vinculin, a protein critical for the function of the interstitial cells of Cajal and the migrating motor complex.
Results are reported as optical density (OD) values for each antibody. Higher values indicate greater antibody elevation. The test reports whether each antibody is positive (elevated above the validated threshold) or negative. A positive result on either antibody is considered a positive test overall, though the anti-vinculin antibody is generally considered more clinically significant because it directly reflects ongoing autoimmune damage to gut motility.
Who should get the ibs-smart test?
- Patients whose chronic gut symptoms (bloating, diarrhea, abdominal pain) began within weeks to months after a food poisoning episode or traveler's diarrhea.
- Patients with recurrent SIBO who relapse after antibiotic or herbal antimicrobial treatment, suggesting an underlying motility defect.
- Patients with an IBS-D diagnosis who have not responded adequately to standard IBS treatments and want to investigate a post-infectious mechanism.
- Patients where differentiating IBS from inflammatory bowel disease (IBD) would be clinically useful, as anti-vinculin antibodies are elevated in IBS but not in IBD.
- Patients who want to understand the root cause of their SIBO to guide long-term management decisions, particularly regarding prokinetic therapy.
How to get the test
The ibs-smart test requires a physician order. It cannot be purchased directly by patients without a clinician's involvement. The test is offered by Gemelli Biotech and can be ordered through their website by a licensed healthcare provider. The blood draw is a standard venipuncture that can be performed at any laboratory or phlebotomy service. No fasting is required. No dietary preparation is needed. There are no medications that need to be stopped before the test. Results are typically available within 7 to 10 business days.
Cost varies depending on insurance coverage. The list price is approximately $220 as of 2026. Some insurance plans cover the test, particularly when ordered by a gastroenterologist with appropriate diagnostic coding (typically IBS-D or functional gastrointestinal disorder codes). Gemelli Biotech offers a patient assistance program for those without insurance coverage.
How to interpret results
A positive anti-CdtB result with a positive anti-vinculin result is the strongest pattern. It indicates both exposure to a CdtB-producing pathogen and active autoimmune damage to the gut motility system. This pattern strongly supports a post-infectious SIBO mechanism and indicates that prokinetic therapy should be a cornerstone of long-term management.
A positive anti-CdtB result with a negative anti-vinculin result indicates past exposure to a CdtB-producing pathogen without measurable autoimmune damage to vinculin. This pattern is less clinically clear. It may indicate early-stage disease, a resolved immune response, or exposure without progression to molecular mimicry. Clinical correlation with symptoms and breath testing is important.
A negative result on both antibodies does not rule out SIBO. It rules out the specific post-infectious autoimmune mechanism detected by the test. SIBO has many potential causes, including structural abnormalities, medication effects, low stomach acid, and non-CdtB-related motility disorders. A negative ibs-smart result means the clinician should investigate other root causes.
âšī¸The ibs-smart test and breath tests answer complementary questions. Breath testing tells you whether you currently have bacterial overgrowth. The ibs-smart test tells you whether the post-infectious autoimmune mechanism is driving that overgrowth. Ideally, both are used together for a complete clinical picture.
ibs-smart vs. breath testing: different tools for different questions
Breath testing (lactulose, glucose, or trio-smart) detects active bacterial overgrowth by measuring gases produced by bacteria fermenting a substrate in the small intestine. A positive breath test confirms current SIBO but says nothing about why the overgrowth is occurring. The ibs-smart test does the opposite: it identifies the autoimmune mechanism that impairs motility but does not measure current bacterial levels. A patient can have a positive ibs-smart test with a negative breath test (if they recently completed antibiotics and the overgrowth has not yet returned) or a positive breath test with a negative ibs-smart (if their SIBO is caused by something other than the post-infectious pathway).
What to do with your results
If your ibs-smart test is positive, the most important clinical implication is that prokinetic therapy should be part of your long-term SIBO management plan. Treating the bacterial overgrowth with rifaximin or herbal antimicrobials addresses the current symptom burden, but without prokinetic support to compensate for the impaired MMC, relapse is likely. Discuss prokinetic options with your physician, including low-dose erythromycin, prucalopride, or low-dose naltrexone. Meal spacing (4 to 5 hours between meals) and avoiding grazing further support MMC function.
If your ibs-smart test is negative, work with your clinician to investigate other SIBO root causes. These include medication effects (PPIs, opioids, anticholinergics), structural issues (adhesions, diverticula, ileocecal valve dysfunction), low stomach acid, and conditions affecting motility through non-autoimmune mechanisms (hypothyroidism, diabetes, Ehlers-Danlos syndrome). A negative ibs-smart result narrows the differential and points toward other avenues of investigation.
â ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.